Related Experiment Video
Updated: Jun 9, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Immunomodulatory drug treatment in multiple sclerosis
1The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel. rina.aharoni@weizmann.ac.il
Expert Review of Neurotherapeutics
|September 8, 2010
Summary
This review covers immunomodulatory therapies for multiple sclerosis (MS), highlighting novel treatments that reduce disease activity but may cause rare, severe side effects like CNS infections.
Area of Science:
- Neuroimmunology
- Immunology
- Neurology
Background:
- Inflammatory processes are central to multiple sclerosis (MS) pathology.
- This understanding drives the development of immunomodulatory therapies.
- These therapies aim to rebalance immune pathways towards anti-inflammatory and regulatory functions.
Purpose of the Study:
- To review current and emerging immunomodulatory strategies for MS.
- To discuss the efficacy and safety profiles of these treatments.
- To explore the potential of these therapies in counteracting inflammation and promoting neuroprotection.
Main Methods:
- Review of scientific literature on immunomodulatory treatments for MS.
- Analysis of clinical trial data (Phase II and III) for efficacy and adverse events.
- Discussion of novel mechanisms of action, including molecular inhibitors, monoclonal antibodies, cell therapies, and oral/infusion agents.
Main Results:
- Several novel immunomodulatory treatments show significant efficacy in reducing MS disease activity and disability progression.
- These advanced therapies offer various mechanisms of action and specificity levels.
- Rare but severe adverse effects, including CNS infections and malignancies, have been observed with potent treatments.
Conclusions:
- Immunomodulatory therapies represent a cornerstone in managing multiple sclerosis.
- Balancing efficacy with the risk of severe adverse events is crucial for treatment selection.
- Future strategies may further enhance neuroprotection alongside immune modulation in MS therapy.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.